This Article Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esmaeli, B. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Esmaeli, B. Articles by Hortobagyi, G. N.

Canalicular Stenosis as the Underlying Mechanism for Epiphora in Patients Receiving Weekly Docetaxel

^a Ophthalmology Section, Department of Plastic Surgery; ^b Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: Bita Esmaeli, M.D., F.A.C.S., Ophthalmology Section, Department of Plastic Surgery, The University of Texas M.D. Anderson Cancer Center, Box 443, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Telephone: 713-794-1247; Fax: 713-794-5492; e-mail: besmaeli{at}mdanderson.org

Weekly administration of docetaxel has emerged as a valuable alternative to an every-3-weeks administration of this drug for treatment of metastatic breast cancer. Baselga and Tabernero should be commended on their informative review of the advantages and side effects of weekly docetaxel administration [1]. The authors state that "a new toxicity of frequent tearing and visual problems, which is generally mild and manageable, may also occur" with weekly administration of docetaxel [1]. Epiphora (excessive tearing) has been reported in up to 50% of patients receiving weekly docetaxel [2]. We believe it is prudent for the readers of The Oncologist to be aware of the mechanism for epiphora in patients receiving weekly docetaxel. We have identified anatomic narrowing of the canaliculi (the first portion of the tear drainage apparatus) as the underlying mechanism for epiphora in at least 23 patients who received weekly docetaxel at a dose of 35-40 mg/m² [3-6]. We have found that this side effect is much more common with weekly administration of docetaxel than with an every-3-weeks administration of this drug and does not respond to conservative measures such as administration of topical steroids or artificial tears [4]. The usual interval between initiation of weekly docetaxel and onset of epiphora is 12 to 16 weeks (with a 3 weeks on, 1 week off schedule of administration). In our experience, most patients who suffer from epiphora are quite bothered by it and believe it significantly affects their quality of life. They report difficulty with reading and driving and dislike the mistaken perception that their tears are due to emotion.

It is important for oncologists to recognize canalicular stenosis as the underlying mechanism for epiphora in patients receiving weekly docetaxel so that consideration can be given to surgical insertion of silicone stents in the nasolacrimal ducts early in the course of chemotherapy. A delay in diagnosis of this side effect can lead to permanent closure of the canaliculi. Once the canaliculi are narrowed to the extent that silicone stents cannot be inserted, a conjunctivodacryocystorhinostomy with placement of a permanent Pyrex glass tube is required to overcome the blockage of the lacrimal outflow. We recommend that patients receiving weekly docetaxel undergo monthly examinations by an ophthalmologist starting as early as possible after initiation of weekly docetaxel so that silicone intubation can be considered as soon as any symptoms of epiphora are noted by the patient. Future prospective studies should focus on determining the frequency and timing of this side effect secondary to various schedules of administration of docetaxel and other taxanes.

References

1. Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. The Oncologist 2001;6(suppl 3):26–29.[Abstract/Free Full Text]
2. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212–1219.[Abstract/Free Full Text]
3. Esmaeli B, Valero V, Ahmadi MA et al. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001;108:994–995.[CrossRef][Medline]
4. Esmaeli B, Hortobagyi GN, Esteva FJ et al. Canalicular stenosis secondary to weekly versus every-three-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2001 (in press).
5. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving weekly docetaxel. Arch Ophthalmol 2001 (in press).
6. Esmaeli B, Hortobagyi G, Esteva F et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2001 (in press).

This article has been cited by other articles:

				N. T. Shah, M. G. Kris, W. Pao, L. B. Tyson, B. M. Pizzo, M.-H. Heinemann, L. Ben-Porat, D. L. Sachs, R. T. Heelan, and V. A. Miller Practical Management of Patients With Non-Small-Cell Lung Cancer Treated With Gefitinib J. Clin. Oncol., January 1, 2005; 23(1): 165 - 174. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esmaeli, B. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Esmaeli, B. Articles by Hortobagyi, G. N.